CA Patent

CA3179420A1 — Coronavirus antigen compositions and their uses

Assigned to Flagship Pioneering Innovations VI Inc · Expires 2021-11-25 · 4y expired

What this patent protects

The disclosure provides compositions and methods comprising circular polyribonucleotides comprising a sequence encoding a coronavirus antigen, and compositions and methods comprising linear polyribonucleotides comprising a sequence encoding a coronavirus antigen. Compositions and…

USPTO Abstract

The disclosure provides compositions and methods comprising circular polyribonucleotides comprising a sequence encoding a coronavirus antigen, and compositions and methods comprising linear polyribonucleotides comprising a sequence encoding a coronavirus antigen. Compositions and methods are provided that are related to generating polyclonal antibodies, for example, using the disclosed circular polyribonucleotides or the disclosed linear polyribonucleotides.

Drugs covered by this patent

Patent Metadata

Patent number
CA3179420A1
Jurisdiction
CA
Classification
—
Expires
2021-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Flagship Pioneering Innovations VI Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.